To substantiate the reported sensitivity of Philadelphia chro-(3.6%) of whom had the Ph chromosome. Twenty-three mosome-positive acute lymphoblastic leukemia (Ph+ ALL) to St patients had abnormalities involving chromosomes 9q34 and The vast majority of children and adolescents with Philadel-
Introduction
The vast majority of children and adolescents with PhiladelTherapy phia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have had a dismal prognosis when treated with chemoThese 23 patients were enrolled in total therapy studies XI (n therapy alone, [1] [2] [3] [4] [5] [6] [7] [8] leading most investigators to favor allo-= 11), XII (n = 6) and XIII (n = 6), 11, 13, 14 in which remissions geneic bone marrow transplantation for patients in first were uniformly induced with prednisone, vincristine, l-asparremission. 9 Recently, however, we reported long-term disaginase, danuorubicin, either teniposide or etoposide, and ease-free survival in three adolescents and one child with cytarabine -followed by intravenous methotrexate (2.0 g/m 2 ) classic Ph+ ALL who had received extensively reinforced early with leucovorin rescue as consolidation therapy. Patients in chemotherapy, followed by rotational treatment with pairs of complete remission in studies XII and XIII were given the non-cross-resistant drugs.
10,11 Thus, a subset of Ph+ cases may option of allogeneic marrow transplantation. be curable with intensive chemotherapy without hematopoContinuation treatment in study XI consisted of rotational ietic stem cell transplantation. The study reported here subadministration of four pairs of drugs (etoposide/ stantiates that prediction and identifies a means by which cyclophosphamide, mercaptopurine/methotrexate, teniposide/ these apparently unique patients can be recognized early in cytarabine and prednisone/vincristine), while study XII specithe clinical course.
fied mercaptopurine/methotrexate, interrupted every 6 weeks for 'pulses' of intravenous methotrexate ( 18 Survival distributions were compared by the exact logrank test, stratified by total therapy Chromosomes were prepared by a direct bone marrow technique as described previously. 15 Metaphases were G-banded study. Time to failure was defined as the interval between the dates of remission and relapse or death from any cause. Patients who did not achieve a remission were assigned a failure time of zero; those who received a bone marrow transplant in first hematological remission (n = 4) were censored at the time of transplantation. Fisher's exact test 19 (for categorical variables) and the Wilcoxon test 19 (for continuous variables) were used to test for the association of presenting clinical and biologic features with initial leukocyte count. The logrank test was used to determine the prognostic importance of candidate variables including age, sex, race, liver or spleen size, the presenting leukocyte count, hemoglobin level, platelet count, presence of leukemic blasts in the cerebrospinal fluid, DNA index, leukemic cell ploidy, serum lactate dehydrogenase level, and expression of myeloid-associated antigens.
Results
Complete remissions were induced in 11 (92%) of the 12 patients treated in study XII or XIII (Table 1) , not significantly different from the induction rate in study XI (82%, P Ͼ 0.05).
Hematologic relapse (at 7, 13, 30 and 34 months) was the primary cause of failure in this group, in contrast to controls, whose remissions were most often ended by early CNS relapse (three of five cases). Disease-free intervals among patients not receiving an allogeneic transplant are 36+, 50+ and 68+ months. None of the long-term responders has developed a second cancer or other serious complication.
Comparison of event-free survival between patients treated in study XII or XIII and study XI (Figure 1a ) indicated no substantial difference in outcome (4-year estimate, 33 ± 19% s.e. vs 36 ± 13%). This analysis included four censored patients who underwent transplantation within 1 year post-diagnosis according to provisions of the treatment protocol. None had signs of impending relapse. Importantly, the profile of the control curve suggests that late relapses should not pose a hazard. Indeed, the four patients included in our previous report 10 have now survived, free of adverse events, for 104+, 106+, 132+ and 143+ months and are likely cured.
Because of the similarity of therapeutic responses in these successive clinical trials, we performed the prognostic factor event-free survival (Figure 1b ; P = 0.004). At 5 years postdiagnosis, the estimated probability of event-free survival in the subgroup with counts р25 × 10 9 /l was 73 ± 19%, comunclear. 10 Here we show that a white blood cell count р25 × 10 9 /l identifies children and adolescents with a high probpared with 10 ± 7% for patients with higher counts. The presence of any number of leukemic cells in the cerebrospinal ability of cure, affording an attractive option in patients for whom bone marrow transplantation is either not feasible or fluid and increased serum levels of lactate dehydrogenase were each significantly associated with white blood cell count refused.
Our findings indicate that Ph+ ALL is a more heterogenous Ͼ25 × 10 9 /l, but neither factor independently predicted outcome.
disease than previously suspected. Variant forms of the Philadelphia chromosome, including the del(22q) alone or complex translocations involving chromosomes 9 and 22, are known to have different molecular lesions and confer a better Discussion prognosis than does the classic rearrangement. 2, 3 However, the paucity of long-term survivors has made it difficult to Since 1984 we have treated 23 patients with ALL and the classic t(9;22)(q34;q11) chromosomal rearrangement, using recognize risk factors among cases with the classic t(9;22). Recently, investigators in the Pediatric Oncology Group extensively reinforced remission induction and consolidation therapy, followed by different approaches to post-remission reported that monosomy 7, found in 23% of their Ph+ ALL cases, increased the risk of failure over that in cases without treatment and preventive CNS therapy. Our initial report suggested that St Jude-type multiagent chemotherapy will cure a this feature. 20 We have not been able to substantiate this observation in the St Jude total therapy series, owing to the subset of Ph+ ALL patients, although the features distinguishing this good-risk group from poor responders were lack of cases with this abnormality.
